Peptides DB
Research-centric peptide and protocol reference hub
Study 62 of 62Semaglutide literatureInternational journal of cardiology · Observational2026

GLP-1 receptor agonist therapy and incident atrial fibrillation in non-diabetic adults with obesity and chronic kidney disease: a propensity matched cohort study.

GLP-1 receptor agonist therapy may be linked to lower rates of atrial fibrillation and related complications in non-diabetic adults with obesity and chronic kidney disease, but further research is needed to confirm these observations.

Read at International journal of cardiologyAdd to compare

Where it sits

this study against the rest of the semaglutide corpus
13
Preclinical
38
Observational · this one
2
Open-label
2
Randomised
7
Reviews

Summary and findings

This study evaluated the impact of GLP-1 receptor agonist therapy on incident atrial fibrillation (AF) in non-diabetic adults with obesity and chronic kidney disease (CKD). A total of 10,985 patients receiving semaglutide, liraglutide, or tirzepatide were compared to 94,527 unexposed patients. The primary outcome was incident AF at 1 year, with significant findings reported.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
HR 0.655, 95% CI 0.508-0.844, p=0.001.n=73262026

Abstract

The authors’ words, as International journal of cardiology supplied them

<h4>Background</h4>Obesity and chronic kidney disease (CKD) are potent risk factors for atrial fibrillation (AF), yet whether GLP-1 receptor agonists (GLP-1RAs) prevent incident AF in non-diabetic adults with obesity and CKD is unexamined. We assessed whether GLP-1RA therapy reduces 1-year AF incidence in this cardiorenal phenotype.<h4>Methods</h4>Using the TriNetX US Collaborative Network (66 healthcare organizations), we conducted a retrospective target trial emulation of non-diabetic adults aged 18 or older with obesity and CKD stages 3-5 diagnosed 2021-2024. Patients receiving semaglutide, liraglutide, or tirzepatide (n = 10,985) were compared with unexposed patients (n = 94,527). After propensity score matching, 7326 patients remained per cohort. The primary outcome was incident AF at 1 year; secondary outcomes included AF subtypes, ventricular tachyarrhythmias, and all-cause hospitalization. Cox models generated hazard ratios (HRs); sensitivity analyses extended follow-up to 2-3 years with landmark analyses.<h4>Results</h4>At 1 year, GLP-1RA use was associated with significantly lower incident AF (1.63% vs. 2.62%; HR 0.655, 95% CI 0.508-0.844; p = 0.001), a 34.5% relative risk reduction. Reductions were consistent for paroxysmal (HR 0.586), persistent (HR 0.482), and longstanding persistent AF (HR 0.527; all p < 0.05); permanent AF was non-significant at 1 year. Ventricular tachyarrhythmias (HR 0.556; p = 0.002) and hospitalization (HR 0.668; p < 0.001) were also significantly reduced. Benefits persisted across 2- and 3-year follow-up and remained consistent in landmark analyses.<h4>Conclusions</h4>In non-diabetic adults with obesity and CKD, GLP-1RA therapy was associated with significant, durable reductions in incident AF, ventricular arrhythmias, and hospitalization. These findings are consistent with a possible cardiorenal benefit and support prioritizing this phenotype for dedicated randomized trials.

Background

This paper addresses the relationship between GLP-1 receptor agonist therapy and the incidence of atrial fibrillation in non-diabetic adults with obesity and chronic kidney disease (CKD). Prior research has established obesity and CKD as significant risk factors for AF, but the potential preventive role of GLP-1RAs in this population had not been thoroughly investigated. Understanding this relationship could inform future clinical practices and research directions.

Methods

The study utilized a retrospective target trial emulation design, analyzing data from the TriNetX US Collaborative Network involving 66 healthcare organizations. The population consisted of non-diabetic adults aged 18 or older with obesity and CKD stages 3-5, diagnosed between 2021 and 2024. A total of 10,985 patients receiving GLP-1RAs (semaglutide, liraglutide, or tirzepatide) were compared to 94,527 unexposed patients, with 7326 patients remaining per cohort after propensity score matching. The primary outcome was incident AF at 1 year, with secondary outcomes including AF subtypes and hospitalization.

Results

At 1 year, GLP-1RA therapy was associated with a significantly lower incidence of AF, with 1.63% in the GLP-1RA group compared to 2.62% in the unexposed group. The hazard ratio for incident AF was 0.655 (95% CI 0.508-0.844; p=0.001), indicating a 34.5% relative risk reduction. Similar reductions were observed for paroxysmal, persistent, and longstanding persistent AF, with all p-values less than 0.05. Additionally, significant reductions were noted for ventricular tachyarrhythmias (HR 0.556; p=0.002) and hospitalization (HR 0.668; p<0.001).

Interpretation

The findings suggest that GLP-1RA therapy may be associated with a reduction in the incidence of AF, which aligns with some previous literature indicating cardiovascular benefits of GLP-1RAs. However, the clinical significance of the observed effect sizes, while statistically significant, may be considered small in a broader clinical context. The retrospective nature of the study and potential confounding factors limit the strength of the conclusions, indicating a need for further randomized controlled trials to confirm these findings.

Key findings

  • 1.63% AF incidence in GLP-1RA group vs 2.62% in unexposed group at 1 year.
  • HR 0.655, 95% CI 0.508-0.844; p=0.001 for incident AF.
  • HR 0.586 for paroxysmal AF, HR 0.482 for persistent AF, HR 0.527 for longstanding persistent AF; all p<0.05.
  • HR 0.556 for ventricular tachyarrhythmias; p=0.002.
  • HR 0.668 for hospitalization; p<0.001.

Limitations

  • Retrospective study design.
  • Observational data may introduce confounding factors.
  • Long-term effects beyond 3 years not established.
  • Potential for selection bias in cohort matching.

Elsewhere in the Semaglutide corpus

BDocumentation of Compounded GLP-1 Receptor Agonists in a Large Primary Care Dataset.Pharmacoepidemiology and drug safety · 2025 · 8.2% of patients used compounded formulations, n=153044.HumanDGLP-1s and criminality: US trial will test whether semaglutide can fight crime.BMJ (Clinical research ed.) · 2026—DThe pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications.Journal of diabetes and metabolic disorders · 2026 · Not reported in abstract.reviewBCardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes.Journal of diabetes and metabolic disorders · 2026 · n=271685 · 4.6% primary composite outcome incidence in tirzepatide group vs. 5.5% in semaglutide group, ARD -0.9%, 95% CI -1.01 to -0.77, HR 0.9, 95% CI 0.92─0.96.HumanBWeight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort.Clinical obesity · 2023 · 30% TWL and 12 kg/m² BMI reduction for SG at 12 months, p < 0.001.HumanDSemaglutide and Suicidality in Adults with Overweight or Obesity: A Bayesian Meta-Analysis of Randomized Trialsbiorxiv-preprint · 2026 · Completed suicide: pooled OR 1.56 (95% CrI 0.55–4.67), P(OR > 1) = 80.6%, n=17,086 semaglutide vs 15,304 placebo.review